A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1 Meeting Abstract

  

Authors:	Linden, H. M.; Campone, M.; Bardia, A.; Ulaner, G. A.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Chandarlapaty, S.
Abstract Title:	A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
Meeting Title:	43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS)
Journal Title:	Cancer Research
Volume:	81
Issue:	4 Suppl.
Meeting Dates:	2020 Dec 8-11
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2021-02-01
Language:	English
ACCESSION:	WOS:000618737700247
PROVIDER:	wos
DOI:	10.1158/1538-7445.SABCS20-PD8-08
Notes:	Meeting Abstract: PD8-08 -- This symposium was held virtually due to COVID-19 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/179244